Schertl, Sabine and Hartmann, Rolf W. and Batzl-Hartmann, Christine and Spruss, Thilo and Maucher, Anton and von Angerer, Erwin and Schiller, Claus D. and Schneider, Martin R. and Gust, Ronald and Schoenenberger, Helmut (2007) Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 133 (3). pp. 153-167. ISSN 0171-5216,
Full text not available from this repository. (Request a copy)Abstract
[Meso-1,2-bis(2,6-dihalo-3/4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-1-PtLL': 2,6-F-2,3-OH; meso-2-PtLL': 2,6-F-2,4-OH; meso-3-PtLL': 2,6-Cl-2,3-OH; meso-4-PtLL': 2,6-Cl-2,4-OH; L = OH2, L' = OSO3 or L,L' = Cl-2) were designed with the aim to get drugs comprising both cytotoxic and testosterone level lowering potencies. It is assumed that such compounds are more efficient than the established endocrine therapeutic measures and can affect the development of hormone refractory prostate cancer (PC). With exception of meso-3-PtLL' all Pt-complexes and the comparison compound cisplatin significantly reduced the testosterone level in experiments on male rats. However, in the test on the Dunning R3327 PC of the rat only cisplatin and meso-4-PtLL' showed a significant anti-tumor activity at well-tolerated dose ranges. Meso-4-PtLL' also significantly extended the time to disease progression in comparison with orchiectomy in this tumor model. Interestingly, the relapsed tumor, too, responded to meso-4-PtLL' as demonstrated in a long-term study on orchiectomized rats bearing Dunning R3327 PC grafts. This effect cannot be ascribed to cytotoxic effects of meso-4-PtLL' because of its inactivity on the human LNCaP/FGC PC cell line. Therefore, the contribution of an additional mechanism to the anti-prostate cancer activity of meso-4-PtLL', presumably owing to its estrogenic potency, must be considered. This assumption was supported by test results with diethylstilbestrol (DES) (non-steroidal estrogen) on the Dunning R3327 PC of the rat relapsed after orchiectomy. This tumor model was strongly inhibited by DES. The possible mode of action of meso-4-PtLL' is thoroughly discussed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TUMOR-INHIBITING ACTIVITY; ANTITUMOR-ACTIVITY; BREAST-CANCER; <1,2-BIS(2,6-DIHALO-3-HYDROXYPHENYL)ETHYLENEDIAMINE>PLATINUM(II) COMPLEXES; PARENTERAL ESTROGEN; ANDROGEN ABLATION; ENDOCRINE THERAPY; CELL-LINES; CARCINOMA; MODEL; [1,2-diphenylethylenediamine] platinum(II) complexes; cisplatin; diethylstilbestrol; anti-prostate cancer activity; mode of action |
| Subjects: | 600 Technology > 615 Pharmacy |
| Divisions: | Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Pharmaceutical/Medicinal Chemistry II (Prof. Buschauer) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Dec 2020 06:44 |
| Last Modified: | 22 Dec 2020 06:44 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33108 |
Actions (login required)
 |
View Item |
